Please login to the form below

Not currently logged in
Email:
Password:

Avandia

This page shows the latest Avandia news and features for those working in and with pharma, biotech and healthcare.

Takeda and Zinfandel abandon Alzheimer’s drug

Takeda and Zinfandel abandon Alzheimer’s drug

In 2010 GlaxoSmithKline went down the same path with its Avandia (rosiglitazone) product, although its failed trial used a different biomarker to determine risk based on cerebrospinal fluid sampling.

Latest news

  • AstraZeneca and its diabetes plans AstraZeneca and its diabetes plans

    When this is put to Boulton, he says: “ I can see where the concern comes from; ten years ago we had metformin, sulphonylureas, insulin and [GSK's type II medicine] Avandia. “

  • AZ's Onglyza may increase mortality, says FDA AZ's Onglyza may increase mortality, says FDA

    The requirement was introduced in the build-up to the withdrawal of GlaxoSmithKline's Avandia (rosiglitazone) from the European market - as well as the imposition of prescribing restrictions in the US -

  • GSK to hire doctors as product champions GSK to hire doctors as product champions

    and Wellbutrin (bupropion) and a failure to report safety data for diabetes drug Avandia (rosiglitazone).

  • FDA to review safety of AZ's saxagliptin FDA to review safety of AZ's saxagliptin

    studies. The requirement was introduced in the build-up to the withdrawal of GlaxoSmithKline's Avandia (rosiglitazone) from the European market and restriction in the US on concerns of cardiovascular toxicity. ... The restricted licence for Avandia in

  • GSK's diabetes drug among CHMP recommendations GSK's diabetes drug among CHMP recommendations

    The drug marks GSK's return to the massive diabetes market following severe restrictions in the US and suspension in the EU for its previous type 2 diabetes product Avandia (rosiglitazone)

More from news
Approximately 3 fully matching, plus 131 partially matching documents found.

Latest Intelligence

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    This has been a consequence of the safety concerns over GlaxoSmithKline's Avandia (rosiglitazone) and the subsequent restrictions, which were then lifted in the US after further analysis.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics